Eligible patients from two randomized controlled trials ( Phase II OV-1002 and Phase III OV-1012 ) were able to enroll in open-label extension ( OLE ) study OV-1004 beginning in December 2005 and received clobazam until they discontinued ( mandatory at 2years for patients outside the United States ) or until study completion in March 2012 .